Triphala and its active constituent chebulinic acid are natural inhibitors of vascular endothelial growth factor-A mediated angiogenesis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Lu, Kai ^a   Chakroborty, Debanjan ^a   Sarkar, Chandrani ^a   Lu, Tingting ^a   Xie, Zhiliang ^a   Liu, Zhongfa ^a,b   Basu, Sujit ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEBULINIC ACID; HERBACEOUS AGENT; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; EMBLICA OFFICINALIS; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; TERMINALIA BELLIRICA; TERMINALIA CHEBULA;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROLYZABLE TANNINS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PLANT EXTRACTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84865281579     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043934     Document Type: Article

References (34)

1. Folkman J, (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
2. Dvorak HF, (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380.
3. Ferrara N, (2009) Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 29: 789-791.
4. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, et al. (2001) The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7: 569-574.
5. Singh DP, Govindarajan R, Rawat AK, (2008) High-performance liquid chromatography as a tool for the chemical standardisation of Triphala- an Ayurvedic formulation. Phytochem Anal 19: 164-168.
6. Pawar V, Lahorkar P, Anantha Narayana DB, (2009) Development of a RP-HPLC method for analysis of Triphala Curna and its applicability to test variations in Triphala Curna preparations. Indian J Pharm Sci 71: 382-386.
7. Baliga MS, (2010) Triphala, Ayurvedic formulation for treating and preventing cancer: a review. J Altern Complement Med 16: 1301-1308.
8. Deep G, Dhiman M, Rao AR, Kale RK, (2005) Chemopreventive potential of Triphala (a composite Indian drug) on benzo(a)pyrene induced forestomach tumorigenesis in murine tumor model system. J Exp Clin Cancer Res 24: 555-563.
9. Sandhya T, Lathika KM, Pandey BN, Mishra KP, (2006) Potential of traditional ayurvedic formulation, Triphala, as a novel anticancer drug. Cancer Lett 231: 206-214.
10. Shi Y, Sahu RP, Srivastava SK, (2008) Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis. BMC Cancer 8: 294.
11. Ferruzzi MG, Lobo JK, Janle EM, Cooper B, Simon JE, et al. (2009) Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease. J Alzheimers Dis 18: 113-124.
12. Seeram NP, Lee R, Heber D, (2004) Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta 348: 63-68.
13. Li L, Wilbur CL, Mintz KL, (2011) Kinetics of hydrothermal inactivation of endotoxins. Appl Environ Microbiol 77: 2640-2647.
14. West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, et al. (2010) Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467: 972-976.
15. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, et al. (2003) A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 10: 823-832.
16. Pyun BJ, Choi S, Lee Y, Kim TW, Min JK, et al. (2008) Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity. Cancer Res 68: 227-235.
17. Sarkar C, Chakroborty D, Chowdhury UR, Dasgupta PS, Basu S, (2008) Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res14: 2502-2510.
18. Chakroborty D, Sarkar C, Yu H, Wang J, Liu Z, et al. (2011) Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci U S A108: 20730-20735.
19. Hussain S, Slevin M, Matou S, Ahmed N, Choudhary MI, et al. (2008) Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis. Angiogenesis 11: 245-256.
20. Istivan TS, Pirogova E, Gan E, Almansour NM, Coloe PJ, et al. (2011) Biological effects of a de novo designed myxoma virus peptide analogue: evaluation of cytotoxicity on tumor cells. PLoS One 6: e24809.
21. Kumar B, Chile SA, Ray KB, Reddy GE, Addepalli MK, et al. (2011) VEGF-C differentially regulates VEGF-A expression in ocular and cancer cells; promotes angiogenesis via RhoA mediated pathway. Angiogenesis 14: 371-380.
22. Bhattacharya R, Sinha S, Yang SP, Patra C, Dutta S, et al. (2008) The neurotransmitter dopamine modulates vascular permeability in the endothelium. J Mol Signal 3: 14.
23. Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, et al. (2009) KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 69: 7175-7179.
24. Pal S, Iruela-Arispe ML, Harvey VS, Zeng H, Nagy JA, et al. (2000) Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade. Microvasc Res 60: 112-120.
25. Ribatti D, Nico B, Vacca A, Presta M, (2006) The gelatin sponge-chorioallantoic membrane assay. Nat Protoc1: 85-91.
26. Labrecque L, Lamy S, Chapus A, Mihoubi S, Durocher Y, et al. (2005) Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis 26: 821-826.
27. Wang Z, Loo WT, Wang N, Chow LW, Wang D, et al. (2012) Effect of Sanguisorba officinalis L on breast cancer growth and angiogenesis. Expert Opin Ther Targets Suppl 1: S79-89.
28. Konishi Y, Hitomi Y, Yoshioka E, (2004) Intestinal Absorption of p-Coumaric and Gallic Acids in Rats after Oral Administration. J Agric Food Chem 52: 2527-2532.
29. Ferruzzi MG, Lobo JK, Janle EM, Cooper B, Simon JE, et al. (2009) Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease. J Alzheimers Dis 18: 113-124.
30. Smart RC, Huang MT, Chang RL, Sayer JM, Jerina DM, et al. (1986) Disposition of the naturally occurring antimutagenic plant phenol, ellagic acid, and its synthetic derivatives, 3-O-decylellagic acid and 3,3′-di-O-methylellagic acid in mice. Carcinogenesis 7: 1663-1667.
31. Russell LH Jr, Mazzio E, Badisa RB, Zhu ZP, Agharahimi M, et al. (2011) Differential cytotoxicity of triphala and its phenolic constituent gallic acid on human prostate cancer LNCap and normal cells. Anticancer Res 31: 3739-3745.
32. Mulder K, Scarfe A, Chua N, Spratlin J, (2011) The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Expert Opin Biol Ther 11: 405-413.
33. Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, et al. (2010) Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf 9: 275-287.
34. Nadler E, Eckert B, Neumann PJ, (2006) Do oncologists believe new cancer drugs offer good value? Oncologist11: 90-95.